Submit Manuscript  

Article Details


MiRNA, a New Treatment Strategy for Pulmonary Fibrosis

[ Vol. 22 , Issue. 7 ]

Author(s):

Yanhong Liu, Hongguang Nie*, Yan Ding, Yapeng Hou, Kejun Mao and Yong Cui   Pages 793 - 802 ( 10 )

Abstract:


Pulmonary fibrosis (PF) is the most common chronic, progressive interstitial lung disease, mainly occurring in the elderly, with a median survival of 2-4 years after diagnosis. Its high mortality rate attributes to the delay in diagnosis due to its generic symptoms, and more importantly, to the lack of effective treatments. MicroRNAs (miRNAs) are a class of small non-coding RNAs that are involved in many essential cellular processes, including extracellular matrix remodeling, alveolar epithelial cell apoptosis, epithelial-mesenchymal transition, etc. We summarized the dysregulated miRNAs in TGF-β signaling pathway-mediated PF in recent years with dual effects, such as anti-fibrotic let-7 family and pro-fibrotic miR-21 members. Therefore, this review will set out the latest application of miRNAs to provide a new direction for PF treatment.

Keywords:

Pulmonary fibrosis, microRNAs, transforming growth factor-β, extracellular matrix, epithelial-mesenchymal transition, pro-fibrotic.

Affiliation:

Department of Stem Cells and Regenerative Medicine, College of Basic Medical Science, China Medical University, Shenyang, Department of Stem Cells and Regenerative Medicine, College of Basic Medical Science, China Medical University, Shenyang, Department of Stem Cells and Regenerative Medicine, College of Basic Medical Science, China Medical University, Shenyang, Department of Stem Cells and Regenerative Medicine, College of Basic Medical Science, China Medical University, Shenyang, Department of Stem Cells and Regenerative Medicine, College of Basic Medical Science, China Medical University, Shenyang, Department of Anesthesiology, the First Affiliated Hospital of China Medical University, Shenyang

Graphical Abstract:



Read Full-Text article